Previous studies described greater efficacy of fg-SRL in DG tumors with higher response rate and a greater reduction in IGF-I levels [28,29]; this observation is, in turn, consistent with the demonstration of a poor SSTR2 representation on cells of somatotroph adenoma with a dot-like cytokeratin pattern [27]. The gene discussed is IGF1; the disease is growth hormone secreting pituitary adenoma 1.